ZA200607806B - Combination therapies with epothilones and carboplatin - Google Patents
Combination therapies with epothilones and carboplatin Download PDFInfo
- Publication number
- ZA200607806B ZA200607806B ZA200607806A ZA200607806A ZA200607806B ZA 200607806 B ZA200607806 B ZA 200607806B ZA 200607806 A ZA200607806 A ZA 200607806A ZA 200607806 A ZA200607806 A ZA 200607806A ZA 200607806 B ZA200607806 B ZA 200607806B
- Authority
- ZA
- South Africa
- Prior art keywords
- epothilone
- carboplatin
- cancer
- patient
- combination
- Prior art date
Links
- 229960004562 carboplatin Drugs 0.000 title claims description 54
- 190000008236 carboplatin Chemical compound 0.000 title claims description 52
- 229930013356 epothilone Natural products 0.000 title claims description 39
- 238000002648 combination therapy Methods 0.000 title description 9
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 title description 9
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 claims description 33
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 claims description 33
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical group O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 claims description 32
- 150000003883 epothilone derivatives Chemical class 0.000 claims description 31
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 9
- 230000001413 cellular effect Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 238000011282 treatment Methods 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 9
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 8
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- PFJFPBDHCFMQPN-RGJAOAFDSA-N (1s,3s,7s,10r,11s,12s,16r)-3-[(e)-1-[2-(aminomethyl)-1,3-thiazol-4-yl]prop-1-en-2-yl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CN)=N1 PFJFPBDHCFMQPN-RGJAOAFDSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- -1 epothilone B lactam Chemical class 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 231100000070 MTS assay Toxicity 0.000 description 2
- 238000000719 MTS assay Methods 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 230000007118 DNA alkylation Effects 0.000 description 1
- BEFZAMRWPCMWFJ-JRBBLYSQSA-N Epothilone C Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C BEFZAMRWPCMWFJ-JRBBLYSQSA-N 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 201000003791 MALT lymphoma Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000008524 alveolar soft part sarcoma Diseases 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- BEFZAMRWPCMWFJ-UHFFFAOYSA-N desoxyepothilone A Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC=CCC1C(C)=CC1=CSC(C)=N1 BEFZAMRWPCMWFJ-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- AEAGZTSEFUFUKN-UHFFFAOYSA-N epothilone 490 Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CC=CC(C)=CCC1C(C)=CC1=CSC(C)=N1 AEAGZTSEFUFUKN-UHFFFAOYSA-N 0.000 description 1
- BEFZAMRWPCMWFJ-QJKGZULSSA-N epothilone C Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QJKGZULSSA-N 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 230000012106 negative regulation of microtubule depolymerization Effects 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Description
COMBINATION THERAPIES WITH EPOTHILONES AND CARBOPLATIN
This invention relates to combination therapies with epothilones and carboplatin and methods for their administration.
The epothilones are potent stabilizers of microtubule formation with a mechanism of action similar to that of paclitaxel: inhibition of tubulin depolymerization and blockage at G2/M of the cell cycle. Of particular interest are epothilone B (1) and its derivatives, for example epothilone B lactam and 21-aminoepothilone B, and epothilone D (2, also known as“KOS-862") and its derivatives. s 0... S
F = —~ 1. OH —~ A. JOH 0
O OH O 0 OH O
Epothilone B (1) Epothilone D (2)
Unlike paclitaxel, epothilone D maintains its potency against paclitaxel resistant human cancer cell lines both in vitro and in vivo. Epothilone D has entered multiple monotherapy Phase 2 clinical trials and shows significant promise in the treatment of ; various cancers.
Combination therapy is important in cancer treatment, as the combination of agents having different mechanisms of action may lead to enhanced cytotoxicity. Since the epothilones (microtubule stabilization) and carboplatin (DNA alkylation) have different mechanisms of antitumor activity, there is potential for non-overlapping toxicities and improved efficacy of an epothilone/carboplatin combination over a taxane/carboplatin combination. The present invention provides combination therapies using epothilone D and carboplatin (Paraplatin™, Bristol-Myers Squibb) that are expected to show significantly improved treatments for various cancers and diseases characterized by cellular hyperproliferation.
0] 0 NH;
Pt Carboplatin o NH3 oO
The invention provides methods for treating diseases characterized by cellular hyperproliferation comprising administering to a patient in need of such treatment a combination of an epothilone and carboplatin. Ina preferred embodiment, the epothilone is epothilone D. In another preferred embodiment, the disease of cellular hyperproliferation is cancer, in particular non-small cell lung cancer. In preferred embodiments, the epothilone is administered before or simultaneously with the carboplatin.
In another embodiment, there is provided a pharmaceutical composition comprising an epothilone together with carboplatin and a pharmaceutically acceptable carrier. The carrier can be, for example, water for injection (WFI).
In another embodiment, there is provided a kit comprising a first pharmaceutical composition comprising an epothilone and a second pharmaceutioal composition comprising carboplatin.
Fig. 1 shows the data for in vitro tests of combinations epothilone and carboplatin.
Figs. 2a and 2b show mouse xenograft data for epothilone-carboplatin combination treatment, compared to either agent alone.
Fig. 3 show cell cycle data for epothilone-carboplatin combination treatment, compared to either agent alone.
In one aspect, the invention provides methods for treating diseases characterized by cellular hyperproliferation comprising administering to a patient (in particular a human) in need of such treatment a combination of an epothilone and carboplatin.
The epothilone used in the pharmaceutical compositions of the invention can be any epothilone, and, more particularly, any epothilone having useful therapeutic properties. Such epothilones can be obtained using any combination of total chemical synthesis, partial chemical synthesis, or chemobiosynthesis methods and materials known to those of skill in organic chemistry, medicinal chemistry, and biotechnology arts.
Specific examples of epothilones having useful therapeutic properties include, but are not limited to, epothilone A, epothilone B, epothilone C, epothilone D, 4-desmethyl- s epothilone D, epothilone B lactam, 21-aminoepothilone B, 9, 10-dehydroepothilone D, 9, 10-dehydro-26-trifluoro-epothilone D, 11-hydroxyepothilone D, 19-oxazolyl- epothilone D, 10, 11-dehydro-epothilone D, and 19-oxazolyl-10, 11-dehydro- epothilone D. In particular embodiments of the invention, the epothilone is selected from the group consisting of epothilone B, epothilone B lactam, 21-aminoepothilone B, epothilone D, and trans-9, 10-dehydroepothilone D. Many detailed examples of suitable epothilones together with methods for their preparation have been published in the literature, with which the skilled practitioner will be familiar.
In certain embodiments of the invention, the disease is cancer. The present invention includes methods for treating cancers of the head and neck which include tumors of the head, neck, nasal cavity, paranasal sinuses, nasopharynx, oral cavity, oropharynx, larynx, hypopharynx, salivary glands, and paragangliomas; cancers of the liver and biliary tree, particularly hepatocellular carcinoma; intestinal cancers, particularly colorectal cancer; treat ovarian cancer; small cell and non-small cell lung cancer; breast cancer sarcomas, such as fibrosarcoma, malignant fibrous histiocytoma, embryonal rhabdomysocarcoma, leiomysosarcoma, neurofibrosarcoma, osteosarcoma, synovial sarcoma, liposarcoma, and alveolar soft part sarcoma; neoplasms of the central nervous systems, particularly brain cancer; lymphomas such as Hodgkin's lymphoma, lymphoplasmacytoid lymphoma, follicular lymphoma, mucosa-associated lymphoid tissue lymphoma, mantle cell lymphoma, B-lineage large cell lymphoma, Burkitt's lymphoma, and T-cell anaplastic large cell lymphoma, among others. In particular embodiments of the invention, the disease is a cancer selected from the group consisting of breast, colorectal, and non-small cell lung cancers.
Clinically, practice of the methods and use of compositions described herein will result in a reduction in the size or number of the cancerous growth and/or a reduction in associated symptoms (where applicable). Pathologically, practice of the method and use of compositions described herein will produce a pathologically relevant response, such as: inhibition of cancer cell proliferation, reduction in the size of the cancer or tumor, prevention of further metastasis, and inhibition of tumor angiogenesis. The method of treating such diseases comprises administering a therapeutically effective amount of an inventive combination to a subject. The method may be repeated as necessary.
In another aspect, the invention provides methods for treating disease comprising administering the combinations described above in certain dosing regimens, described herein. The epothilone can be administered simultaneously with carboplatin.
Alternatively, the epothilone can be administered prior to administration of carboplatin, or carboplatin may be administered before the epothilone. In addition, for those embodiments in which the two agents are administered separately, the administration of the second agent can be delayed to provide greater therapeutic effect of the combination therapy. Those having skill in the pharmacology and medicine arts will be familiar with concepts, methods, and materials suitable to determine the temporal factors in administering non-simultaneous therapies. Example of relevant factor may include, but are not limited to, the patient’s circadian rhythm, cell cycle characteristics relevant to the disease being treated (e.g., tumor cell type), and the pharmacokinetic parameters of the drugs being used.
In another aspect, the invention provides pharmaceutical compositions comprising an epothilone together with carboplatin and a pharmaceutically acceptable carrier. The epothilone and the carboplatin are provided in the appropriate ratio to provide the effective therapeutic doses of the two agents.
In another aspect, the invention provides kits that facilitate the combination therapy using the epothilone and carboplatin as separate agents. In one embodiment, such kits comprise separate pharmaceutical compositions for the two agents, that is, a first pharmaceutical composition comprising an epothilone and a second pharmaceutical composition comprising carboplatin. These pharmaceutical compositions may be concentrates or lyophilates comprising the epothilone or the carboplatin in appropriate amounts together with required excipients, ready for dilution with an aqueous medium prior to injection into the patient, or they may be lipid emulsions ready for direct injection into the patient.
The following Examples merely illustrate certain aspects of the present invention : to aid those of skill in the art in practicing the invention, and do not limit the scope of the invention in any manner.
Example 1 — Synergy between Epothilone D and Carboplatin in Cultured NSCLC.
Cell Lines
The human NSCLC (non-small cell lung cancer) cell lines A549, H23, H226,
H358, H460, and H522 were seeded in 96 well plates (5000 cells/well); after overnight incubation, the cells were treated with epothilone D or carboplatin alone or epothilone D and carboplatin in combination. Once the ICs, value of each drug was obtained, the combined drug treatment was designed at constant ratios of the two drugs and the treatment schedule varied: either epothilonc D or carboplatin was administered first with the second drug added 24 hours later. Cell viability was assayed by the MTS assay.
While mild antagonism was observed when carboplatin was administered first, marked synergy was measured when epothilone D was initially administered followed by the carboplatin in all cell lines tested. As shown in Table 1, epothilone D shows potent cytotoxic effects against a range of cultured non-small cell lung cancer (NSCLC) human cancer cell lines, whereas carboplatin is essentially inactive at a concentration of 10,000 nM. Cells were treated with epothilone D or carboplatin at varying concentrations, ranging from 1 pM to 10 uM, for 3 days. Cell viability was determined using the using the MTS assay (Promega). ICs is defined as the concentration of drug required to inhibit cell growth by 50%.
Activity of Epothilone or Carboplatin Alone against Human NSCLC Cell Lines
EE EE SE I
Fig. 1 shows the results of the combination experiments. In all six cell lines, treatment with epothilone D first followed by carboplatin resulted in strong synergy, whereas treatment with carboplatin first followed by epothilone D resulted in mild antagonism. Since carboplatin is shown in Table 1 to be essentially inactive against
NSCLC cell lines, the occurrence of synergism in a combination therapy with an cpothilone is unexpected.
Example 2 — Synergy between Epothilone D and Carboplatin in Mouse Xenografts
The drug combination was also tested in nude mice bearing the human lung cancer xenografts MV522 and SK-MES. Fragments of human tumor carcinomas harvested from subcutaneously growing tumors in nude mice hosts were implanted subcutaneously. When tumors were approximately 60-75 mg in size (10-14 days after implantation), mice were pair matched into treatment and control groups. Epothilone D was given intraperitoneally twice a day for 7 days (6 to 14 mg/kg/day), carboplatin intraperitoneally every daily for 5 days (10 to 40 mg/kg/day), various combinations of epothilone D (first) and carboplatin (second), or vehicle control. Epothilone D and carboplatin as single agents exerted antiproliferative activity (measured as tumor size) in a dose dependent manner. None of the drug combinations resulted in antagonism while multiple combinations demonstrated additive or synergistic effects under conditions where weight loss of the animals was well tolerated and reversible. The results on an experiment wherein the animals were treated with vehicle, epothilone D (8 mg/kg for
MV522 and 14 mg/kg for SKMES, twice a day for 7 days) alone, or carboplatin (10 mg/kg, once daily, for 5 days) alone, or epothilone D followed by carboplatin, are shown in Fig. 2. In the MV522 and SKMES xenograft models, the combination therapy of epothilone D and carboplatin produced a strong tumor inhibition at doses that were significantly less than for single-agent therapy of either drug. The total body weight loss of the animals was well tolerated and reversible.
Example 3 — Effects of Epothilone D and Carboplatin on Cell Cycles
Cells were treated with epothilone D alone (8 nM), carboplatin alone (15 uM), or with epothilone D (8 nM) followed by carboplatin (15 uM). Cells were stained with propidium iodide and analyzed by flow cytometry. Results are shown in Fig. 3.
Treatment of cells with a combination of epothilone D and carboplatin results in an increased sub-G, population, indicating the induction of apoptosis.
The foregoing detailed description of the invention includes passages that are chiefly or exclusively concerned with particular parts or aspects of the invention. It is to be understood that this is for clarity and convenience, that a particular feature may bc relevant in more than just the passage in which it is disclosed, and that the disclosure herein includes all the appropriate combinations of information found in the different passages. Similarly, although the various figures and descriptions hercin relate to specific embodiments of the invention, it is to be understood that where a specific feature is disclosed in the context of a particular figure or embodiment, such feature can also be used, to the extent appropriate, in the context of another figure or embodiment, in combination with another feature, or in the invention in general.
Further, while the present invention has been particularly described in terms of certain preferred embodiments, the invention is not limited to such preferred embodiments. Rather, the scope of the invention is defined by the appended claims.
Claims (17)
1. Use of an epothilone and carboplatin in the munufacture of a medicament for treating diseases characterized by cellular hyperproliferation in a patient.
2. Use of an epothilone in the manufacture of a medicament for use with carboplatin for treating diseases characterized by cellular hyperproliferation in a patient.
3. Use of carboplatin in the manufacture of a medicament for use with an epothilone for treating diseases characterized by cellular hyperproliferation in a patient.
4. Use of any one of claims 1 to 3, wherein the epothilone is epothilone D.
5. Use of claim 4, wherein the disease is cancer.
6. Use of claim 5, wherein the disease is non-small cell lung cancer.
7. Use of any one of claims 1 to 3, wherein the disease is cancer.
8. Use of claim 7, wherein the disease is non-small cell lung cancer.
9. Use of claim 2 or 3, wherein the patient is first treated with the epothilone, and subsequently is treated with carboplatin.
10. Use of any one of claims 1 to 3, wherein the patient is treated simultaneously with the epothilone and with carboplatin.
11. A pharmaceutical composition comprising an epothilone together with carboplatin and a pharmaceutically acceptable carrier.
12. The pharmaceutical composition of claim 11, wherein the epothilone is epothilone
D. -8- AMENDED SHEET
PCT/US2005/009657
13. A kit comprising a first pharmaceutical composition comprising an epothilone and a second pharmaceutical composition comprising carboplatin.
14. The kit of claim 13, wherein the epothilone is epothilone D.
15. Use of any one of claims 1 to 10, substantially as herein described with reference to and as illustrated in any of the examples and accompanying figures.
16. A composition of claim 11 or claim 12, substantially as herein described with reference to and as illustrated in any of the examples and accompanying figures.
17. A kit of claim 13 or claim 14, substantially as herein described with reference to and as illustrated in any of the examples and accompanying figures. -9- AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55685604P | 2004-03-26 | 2004-03-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200607806B true ZA200607806B (en) | 2008-06-25 |
Family
ID=37879350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200607806A ZA200607806B (en) | 2004-03-26 | 2006-09-18 | Combination therapies with epothilones and carboplatin |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN1934269A (en) |
ZA (1) | ZA200607806B (en) |
-
2005
- 2005-03-24 CN CN 200580009437 patent/CN1934269A/en active Pending
-
2006
- 2006-09-18 ZA ZA200607806A patent/ZA200607806B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1934269A (en) | 2007-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fumoleau et al. | Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues | |
AU2927999A (en) | Use of epothilones for the treatment of cancer | |
JP2002504511A5 (en) | ||
US20040167097A1 (en) | EPO D + 5-FU/gemcitabine | |
AU2009215329B2 (en) | Combination comprising paclitaxel for treating ovarian cancer | |
JP2009536956A (en) | Anticancer therapy | |
EP2965757A1 (en) | Pharmaceutical compositions for treating malignant glioma | |
US9937261B2 (en) | Combination therapy comprising a liposomal prodrug of mitomycin C and radiotherapy | |
CN111902147A (en) | Combination cancer therapy of pentaazamacrocycle complexes and platinum-based anticancer agents | |
US20050215604A1 (en) | Combination therapies with epothilones and carboplatin | |
ZA200607806B (en) | Combination therapies with epothilones and carboplatin | |
MXPA06010921A (en) | Combination therapies with epothilones and carboplatin | |
US20170087120A1 (en) | Composition for improving bioavailbility and efficacy of taxane | |
WO2009104152A1 (en) | Combination treatment for ovarian cancer | |
Mani et al. | Ixabepilone | |
CA2530311A1 (en) | Cancer treatment with epothilones | |
Egerton | Ixabepilone Treatment Schedules in Advanced Breast Cancer | |
WO2004073719A1 (en) | A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent | |
MXPA06005359A (en) | Combination therapy comprising the use of et-743 and paclitaxel for treating cancer |